Pulmonary Artery Pressure-Guided Heart Failure Management: US Cost-Effectiveness Analyses Using the Results of The CHAMPION Clinical Trial

Abstract

Standard economic modelling suggests that pulmonary artery pressure-guided management of HF using the CardioMEMS™ HF System is cost-effective from the US-payer perspective. This analysis provides the background for further modelling in specific country healthcare systems and cost structures.